Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis

OBJECTIVES: To assess structural damage progression with subcutaneous abatacept (ABA) in the Assessing Very Early Rheumatoid arthritis Treatment (AVERT) trial following abrupt withdrawal of all rheumatoid arthritis (RA) medication in patients achieving Disease Activity Score (DAS)-defined remission...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Ann Rheum Dis
Asıl Yazarlar: Peterfy, Charles, Burmester, Gerd R, Bykerk, Vivian P, Combe, Bernard G, DiCarlo, Julie C, Furst, Daniel E, Huizinga, Tom W J, Wong, Dennis A, Conaghan, Philip G, Emery, Paul
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BMJ Publishing Group 2016
Konular:
Clinical and Epidemiological Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4975847/
https://ncbi.nlm.nih.gov/pubmed/26865601
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2015-208258
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller